Physician profile
Thomas B Edwards
NPI 1740215771
$23,106.76
in general payments reported to CMS, 2019-2025
32 companies · $3,327 in 2025
The $3,327 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,834 · 2020: $931 · 2021: $1,830 · 2022: $7,510 · 2023: $2,653 · 2024: $4,022 · 2025: $3,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,952 · Education: $49.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,952.43 |
| Education | $49.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,482.23 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Blueprint Medicines Corporation | $5,366.63 | 2021-2025 | Ayvakit |
| Glaxosmithkline, LLC. | $2,498.88 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,444.48 | 2019-2025 | Dupixent |
| Pfizer INC. | $847.79 | 2019-2025 | |
| Genzyme Corporation | $781.50 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $778.59 | 2019-2025 | |
| Csl Behring | $776.07 | 2022-2025 | Hizentra, Haegarda, Andembry |
| Genentech USA, INC. | $754.63 | 2019-2025 | Xolair |
| Amgen INC. | $644.83 | 2022-2025 | Tezspire, Actimmune |
| Pharming Healthcare, INC. | $484.40 | 2021-2025 | Ruconest |
| Grifols USA, LLC | $439.52 | 2019-2025 | Prolastin-C Liquid, Xembify, Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.11 | 2019-2024 | Spiriva Respimat |
| Optinose US, INC. | $309.22 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $295.87 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $269.87 | 2021-2025 | Cuvitru, Takhzyro |
| Kaleo, INC. | $246.56 | 2019-2023 | Auvi-Q |
| Biocryst US Sales Co., LLC | $243.73 | 2021-2024 | Orladeyo |
| Abbvie INC. | $232.49 | 2022-2025 | Rinvoq |
| Aimmune Therapeutics, INC. | $147.19 | 2020-2023 | |
| Lilly USA, LLC | $119.17 | 2024-2025 | Ebglyss |
| Dermavant Sciences, INC. | $105.32 | 2024 | Vtama |
| Sanofi-Aventis U.S. LLC | $97.49 | 2020-2022 | |
| Greer Laboratories, INC. | $95.57 | 2025 | Oralair |
| Octapharma USA, INC. | $88.21 | 2019-2020 | |
| Adma Biomanufacturing LLC | $51.00 | 2025 | |
| Gc Biopharma USA, INC. | $48.77 | 2025 | Alyglo |
| Galderma Laboratories, L.P. | $48.60 | 2025 | Nemluvio |
| Leo Pharma INC. | $41.75 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $21.22 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $17.04 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Edwards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.